Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses
1999; Wiley; Volume: 60; Issue: 5 Linguagem: Inglês
10.1002/(sici)1096-9926(199911)60
ISSN2472-1727
AutoresMarilyn T. Miller, Kerstin Str�mland,
Tópico(s)Ocular Diseases and Behçet’s Syndrome
ResumoTeratologyVolume 60, Issue 5 p. 306-321 Teratogen UpdateFull Access Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses Marilyn T. Miller, Corresponding Author Marilyn T. Miller Department of Ophthalmology, Eye and Ear Infirmary, University of Illinois, Chicago, Illinois 60612Department of Ophthalmology and Visual Science, Eye and Ear Infirmary, University of Illinois, 1855 West Taylor Street, Chicago, IL 60612.Search for more papers by this authorKerstin Strömland, Kerstin Strömland Department of Ophthalmology, Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital/East, Se-416851 Göteborg, SwedenSearch for more papers by this author Marilyn T. Miller, Corresponding Author Marilyn T. Miller Department of Ophthalmology, Eye and Ear Infirmary, University of Illinois, Chicago, Illinois 60612Department of Ophthalmology and Visual Science, Eye and Ear Infirmary, University of Illinois, 1855 West Taylor Street, Chicago, IL 60612.Search for more papers by this authorKerstin Strömland, Kerstin Strömland Department of Ophthalmology, Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital/East, Se-416851 Göteborg, SwedenSearch for more papers by this author First published: 18 October 1999 https://doi.org/10.1002/(SICI)1096-9926(199911)60:5 3.0.CO;2-YCitations: 127AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat LITERATURE CITED Alexander LN, Wilcox CM. 1997. A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. Aids Res Hum Retroviruses 13: 301–304. Medline Arimoto Y. 1987. Ophthalmology in thalidomide embryopathy. In: M Kida, editor. Thalidomide embryopathy in Japan. Tokyo: Kodansha. p 143–153. Argiles JM, Carbo N, Lopez-Soriano FJ. 1998. Was a tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypothesis 50: 313–318. Asscher W. 1994. Safety of thalidomide. Br Med J 309: 193–194. Ball SC, Sepkowitz KA, Jacobs JL. 1997. Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review. Am J Gastroenterol 92: 169–170. Medline Balog DL, Epstein ME, Amodio-Groton MI. 1998. HIV wasting syndrome: treatment update. Ann Pharmacother 32: 446–458. Medline Bauer KS, Dixon SC, Figg WD. 1998. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827–1834. Medline Barinaga M. 1997. Designing therapies that target tumor blood vessels. Science 275: 482–484. Medline Bessis D, Guillot B, Monpoint S, Dandurand M, Guihou JJ. 1992. Thalidomide for systemic lupus erythematosus. Lancet 338: 549–550. Bielsa I, Teixido J, Ribera M, Ferrandiz C. 1994. Erythroderma due to thalidomide: report of two cases. Dermatology 189: 179–181. Medline Brent RL, Holmes LB. 1988. Clinical and basic science from the thalidomide tragedy: what have we learned about the causes of limb defects? Teratology 38: 241–251. Medline Brown D. 1994. Once-reviled thalidomide shows promise as AIDS treatment. Washington Post, Science/Medicine, July 18, A3. Browne WL, Wilson WR, Baguley BC, Ching LM. 1998. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res 18: 4409–4413. Medline Calderon P, Anzilotti M, Phelps R. 1997. Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 36: 881–887). Medline Carmichael AJ, Knight A. 1992. Thalidomide: a restricted role. Teratology 339: 1362. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J, Delgadillo JL, Dutra MG, Felix T, Giraldo A, Juarez N, Lopez-Camelo JS, Nazer J, Orioli IM, Paz JE, Pessoto MA, Pino-Neto JM, Quadrelli R, Rittler M, Rueda S, Saltos M, Sanchez O, Schuler L. 1996. Thalidomide, a current teratogen in South America. Teratology 54: 273–277. Medline Centers for Disease Control and Prevention. 1993. Revised classification systems for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41: 1–19. Cherouati K, Claudy A, Souteyrand P, Cambazard F, Vaillant L, Molin F, Crickx B, Morel P, Lamorelle A, Revuz J. 1996. Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants: a retrospective study of 26 patients. Ann Dermatol Venereol 123: 375–377. Medline Crawford CL. 1994a. Safety of thalidomide. Br Med J 308: 1437–1438. Comments: Br Med J 309: 193–194. Crawford CL. 1994b. Use of thalidomide in leprosy. Adv Drug React Toxicol 13: 177–192. Cullen JF. 1964. Ocular defects in thalidomide babies. Br J Ophthalmol 48: 151–153. Cutler J. 1994. Thalidomide revisited. Lancet 343: 795–796. D'Amata RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085. Medline D'Amata RJ, Verheul HMW, Panigrahy D, Yuan J. 1997. Combination antiangiogenic therapy with thalidomide and nonsteroidal anti-inflammatory drugs (NSAIDs). Invest Ophthalmol Vis Sci 38: S964 (abstract). d'Avignon M, Barr B. 1964. Ear abnormalities and cranial nerve palsies in thalidomide children. Arch Otolaryngol 80: 136–140. d'Avignon M, Hellgren K, Juhlin I, et al. 1967. Diagnostic and habilitation problems of thalidomide-traumatized children with multiple handicaps. Dev Med Child Neurol 9: 707–712. Duna GF, Cash JM. 1995. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin N Am 21: 99–115. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. 1998. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 9: 751–755. Medline Folkman J. 1995. Clinical applications of research on angiogenesis. New Engl J Med 333: 1757–1763. Medline Fraser FC. 1988. Thalidomide retrospective: what did we learn. Teratology 38: 201–202. Medline Frost N. 1997. Ethical issues in the use of thalidomide in fertile women. Presented at the thalidomide: potential benefits and risks symposium. National Institutes of Health, September 9–10, Bethesda, MD. Gardner-Medwin JMM, Smith NJ, Powell RJ. 1994. Clinical experience with thalidomide in the management of severe oral and gential ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53: 828–832. Medline Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, Kraft A. 1997. Angiogenesis as a target for tumor treatment. Oncology 54: 177–184. Medline Gilkes MT, Strode M. 1963. Ocular anomalies in association with developmental limb abnormalities of drug origin. Lancet 1: 1026–1027. Godfrey T, Khamashta MA, Huges GR. 1998. Therapeutic advances in systemic lupus erythematosus. Curr Opin Rheumatol 10: 435–441. Medline Hashimoto Y, 1998. Novel biological response modifiers derived from thalidomide. Curr Med Chem 5: 163–178. Medline Hawkins DF. 1992. Thalidomide for systemic lupus erythematosis. Lancet 339: 1057. Honegger H, Pape R. 1964. Thalidomid und angeborene Fehlbildungen der Augen. Ber Dtsch Ophthalmol Ges 65: 222–223. Huizinga TWJ, Dijkmans BAC, van der Velde EA, van de Pouw Kraan TCTM, Verweij CL, Breedveld FC. 1996. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 55: 833–836. Medline Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, and Wohl DA. 1997. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. New Engl J Med 336: 1487–1493. Medline Jakeman P, Smith WCS. 1994. Thalidomide in leprosy reaction. Lancet 343: 432–433. Medline Jampel RS, Titone C. 1962. Congenital paradoxical gustatory-lacrimal reflex and lateral rectus paralysis. Arch Ophthalmol 67: 123–126. Jones GR. 1994. Thalidomide: 35 years on and still deforming (letter). Lancet 343: 1041–1042. Comment - Lancet, 19:343( 432–433) Joseph IB, Isaacs JT. 1998. Macrophage rule in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 90: 1648–1653). Medline Joussen AM, Kruse FE, Becker K, Rohrschneider HE. 1997. Thalidomide inhibits angiogenesis induced by vascular endothelial growth factor (abstract). Invest Ophthalmol Vis Science 38: 359. Kajii T. 1965. Thalidomide experience in Japan. Ann Pediatr 205: 341–354. Kelsey FO. 1988. Thaldiomide update: regulatory aspects. Teratology 38: 221–226. Medline Kida M, Hayashi H, Tanaka M, Matsumoto Y, Iwakura H, Arima H, Asaka A, Gomi S. 1978. Various kinds of symptoms seen in 36 children with thalidomide embryopathy. Teikyo Igaku Zasshi, 1: 131–137. Kida M. 1987. Thalidomide embryopathy in Japan. Tokyo: Kodansha. Klausner JD, Freedman VH, Kaplan G. 1996a. Short analytical review: thalidomide as an anti-TNF—α inhibitor: implications for clinical use. Clin Immunol and Immunopathol 81: 219–223. Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinerk W, Corral L, Dewar RL, Lane HC, Freedman VH, Kaplan G. 1996b. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 11: 247–257. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, Macher E. 1983. Thalidomide in the treatment of 60 cases of chronic discoid lupus erythematosus. Br J Dermatol 108: 461–466. Medline Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. 1998. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236: 461–466. Medline Lair GI, Marie I, Cailleux N, Blot E, Boullie MC, Courville P, Lauret P, Levsque H, Courtois H. 1998. Langerhans histiocytosis in adults: cutaneous and mucous lesion regression afer treatment with thalidomide). Rev Med Interne 19: 196–198. Medline Larsson H. 1990. Treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217). J Intern Med 228: 405–407. Medline Leck IM, Millar ELM. 1962. Incidence of malformations since the introduction of thalidomide. Br Med J 2: 16–20. Lee JB, Koblenzer PS. 1998. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Cermatol 39: 835–838. Lenz W. 1961a. Diskussionsbemerkung zu dem Vortrag von R.A. Pfeiffer und K. Kosenow: zur Frage der exogenen Entstehung schwere Extrëmitatenmissbildungen. Tagung Rheinischwestfal Kinderarztevere Dusseldorf 19: 11. Lenz W. 1961b. Fragen aus der Praxis: kindliche Missbildungen nach Medikament Einnahme während der Graviditat? Dtsch Med Wochenschr, 86: 2555–2556. Lenz W. 1962. Thalidomide and congenital abnormalities. Lancet 1: 271–272. Lenz W, Knapp K. 1962. Die thalidomide-embryopathie. Dtsch Med Wochenschr 87: 1232–1242. Lenz W. 1966. Malformation caused by drugs in pregnancy. Am J Dis Child 112: 99–106. Medline Lenz W. 1985. Thalidomide embryopathy in Germany. In: M Marois, editor. Prevention of physical and mental congenital defects. Part C: basic and medical science education and future strategies: New York: Liss. p 77–83. Lenz W. 1988. A short history of thalidomide embryopathy. Teratology 38: 203–215. Medline McBride WG. 1961. Thalidomide and congenital abnormalities. Lancet 2: 1358. McBride WG. 1977. Thalidomide embryopathy. Teratology 16: 79–82. Medline Miehlke AU, Partsch CJ. 1963. Ohrmissbidung, facialis-und abducenslähmung als syndrom der thalidomidschädigung. Arch Ohrenusw Heilk u 2.Halsuw 181: 154. Miller JM, Ginsberg M, McElfatick GC, Shonberg IL. 1960. The anti-inflammatory effect and the analgesic property of thalidomide - 268. Antibiot Med Clin Ther 7: 743–746. Miller MT, Strömland K. 1991. Ocular motility in thalidomide embryopathy. J Pediatr Ophthalmol Strabismus 28: 47–54. Medline Miller MT. 1991. Thalidomide embryopathy: a model for the study of congenital incomitant horizontal strabismus. Trans Am Ophthalmol Soc 89: 623–674. Medline Miyachi H, Azuma A, Hioki E, Iwasaki S, Kobayashi Y, Hashimoto Y. 1996. Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor—α production and its enantio-dependence. Biochem Biophys Res Commun 226: 439–444. Medline Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, Freedman VH, Kaplan G. 1997. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 13: 857–863. Medline Muller-Quernheim J. 1998. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 12: 716–738. Medline Neubert R, Hinz N, Thiel R, Neubert D. 1996. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 58: 295–316. Medline Newmann CGH. 1977. Clinical observations on the thalidomide syndrome. Proc Roy Soc Med 70: 225–227. Nightingale SL. 1998. From the Food and Drug Administration: thalidomide approved for erythema nodosum leprosum. JAMA 280: 872. Medline Nogueira AC, Neubert R, Felies A, Jacob-Muller U, Frankus E, Neubert D. 1996. Thalidomide derivatives and the immune system 6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets. Life Sci 58: 337–348. Medline Nowack E. 1965. Die sensible Phase bei der thalidomid-embryopathie. Humangenetik 1: 516–536. Medline Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. 1994. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 130: 66–69. Medline Papst W. 1964. Thalidomid und kongenitale Anomalien der Augen. Ber Dtsch Ophthalmol Ges 65: 209–215. Papst WE, Esslen E. 1964. Symptomatology and therapy in ocular motor disturbance. Am J Ophthalmol 58: 275–291. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. 1995. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 20: 250–254. Medline Pliess G. 1962. Thalidomide and congenital abnormalities. Lancet 2: 1128–1129. Postema PT, den Haan P, van Hagen PM, van Blankenstein M. 1996. Treatment of colitis in Behcet's disease with thalidomide. Eur J Gastroenterol Hepatol 8: 929–931. Medline Powell RJ, Gardner-Medwin JMM. 1997. Guidelines for the clinical use and dispensing of thalidomide. Postgrad Med J 68: 61–66. Ramsay J, Taylor D. 1980. Congenital crocodile tears: a key to the aetiology of Duane's syndrome. Br J Ophthalmol 64: 518–522. Medline Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruz-Palacios GM. 1996. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo controlled clinical trial. AIDS, 10: 1501–1507. Rhodes J, Thomas G, Evans BK. 1997. Inflammatory bowel disease management. Drugs 53: 189–194. Medline Robert E. 1996. Thalidomide and isotretinoin: why treat them differently? Reprod Toxicol 10: 1–2. Medline Rovelli A, Arrigo C, Nesi F, Balduzzi A, Nicolini B, Locasciulli A, Vassallo E, Miniero R, Uderzo E. 1998. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow. Bone Marrow Transplant 21: 577–581. Medline Saito A, Asaha A. 1987. A psychological study of patients with thalidomide embryopathy. In: M Kida, editor. Thalidomide embryopathy in Japan. Tokyo: Kodansha. Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, Sarno EN. 1993. The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum. J Infect Dis 168: 408–414. Medline Santos-Mendoza T, Favila-Castillo L, Oltra A, Tamariz J, Labarrios F, Estrada-Parra S, Estrada-Garcia L. 1996. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Int Arch Allergy Immunol 111: 13–17. Medline Sato EI, et al. 1998. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Asso Med Bras 44: 289–298. Schmidt JGH. 1964. Augenmuskelparesen bei Thalidomid-embryopathie. Bericht Deutsch Ophthal Ges 1964; 65: 215–220. Shannon EJ, Sandoval F, Krahenbuhl JL. 1997. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF—α Immunopharmacology 36: 9–15. Medline Sheskin J. 1965. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6: 303–306. Sheskin J. 1980. The treatment of lepra reactions in lepramatous leprosy: 15 years' experience with thalidomide. Int J Dermatol 19: 328. Smithells RW. 1962. Thalidomide and malformations in Liverpool. Lancet i: 1270–1273. Smithells RW. 1973. Defects and disabilities of thalidomide children. Br Med J 1: 269–272. Medline Soler RA, Migliorati C, van Waes H, Nadal D. 1996a. Thalidomide treatment of mucosal ulcerations in HIV infection. Arch Dis Child 74: 64–65. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D. 1996b. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 23: 501–503. Somers GF. 1960. Pharmacological properties of thalidomide (-α [N-phthalimido] - glutarimide): a new sedative hypnotic drug. Br J Pharmacol 15: 111–116. Stephens TD. 1988. Proposed mechanisms of action in thalidomide embryopathy. Teratology 38: 229–239. Medline Stevens RJ, Andujar C, Edwards CJ, Ames PRJ, Barwick AR, Khamashta MA, Hughes GR. 1997. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in 16 consecutive patients. Br J Rheumatol 36: 353–359. Medline Stirling DI. 1995. Potential use of thalidomide in HIV/AIDs. Am Rev Med Chem 30: 319–327. Stirling DI, Sherman M, Strauss S. 1997. Thalidomide: a surprising recovery. J Am Pharmacol Assoc NS37: 307–313. Stirling DI. 1998. Thalidomide and its impact in dermatology. Semin Cutan Med Surg 17: 231–242. Medline Strömland K, Miller MT. 1992. Refractive evaluation in thalidomide embryopathy. Graefe Arch clin Exp Ophthalmol, Springer-Verlag, 230: 140–149. Strömland K, Miller MT. 1993. Thalidomide embryopathy: revisited 27 years later. Acta Ophthalmol 71: 238–245. Strömland K, Nordin V, Miller M, Akerström B, Gillberg C. 1994. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 36: 351–356. Medline Tachibana M, Hoshino A, Oshima W, Nishimura H, Mizukoshi O. 1984. Duane syndrome associated with crocodile tear and ear malformations. Arch Otolaryngol 110: 761–762. Medline Takemori S, Tanaka Y, Suzuki JI. 1976. Thalidomide anomalies of the ear. Arch Otolaryngol 102: 425–427. Medline Taussig HB. 1962. Thalidomide and phocomelia. Pediatrics 30: 654–659. Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. 1997. Thalidomide reduces tumour necrosis factor—α production by human alveolar macrophages. Respir Med 91: 31–39. Medline Teixeira F, Hojyo MT, Arenas R, Vega ME, Cortes R, Ortiz A, Dominguez L. 1994. Thalidomide: can it continue to be used? Lancet 344: 196–197. Thalidomide: potential benefits and risks symposium (1997). National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention, September 9–10, Bethesda, MD. Therapeutic Teratology. 1996. 1996 Teratology Society of Public Affairs Symposium. Teratology 54– 303–304. Medline Tracey KJ, Cerami A. 1994. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45: 491–503. Medline Tramontana JM, Utaipat U, Molloy A, Akarasew P, Burroughs M, Makonkawlreyoon S, Johnson B, Klausner JD, Rom W, Kaplan G. 1995. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1: 384–397. Medline Trussell J. 1995. Contraceptive efficacy. Arch Dermatol 131: 1064–1068. Medline Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. 1996. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35: 969–979. Medline Turk BE, Jiang H, Liu JO. 1996. Binding of thalidomide to -α 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor—α production. Proc Natl Acad Sci USA 93: 7552–7556. Medline Uthoff K, Zehr KJ, Gaudin PB, Kumar P, Cho PW, Vogelsang G, Hruban RH, Baumgartner WA, Stuart RS. 1995. Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann Thorac Surg 59: 277–282. Medline Verberkmoes A, Boer K, Wertheim PME, Bronkhorst CM, Lange JMA. 1996. Thalidomide for genital ulcer in HIV-positive woman. Lancet 347: 974. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW. 1992. Thalidomide for the treatment of chronic graft-vs-host disease. N Engl J Med 326: 1055–1058. Medline Warkany J. 1988. Why I doubted that thalidomide was the cause of limb defects of 1959–1961. Teratology 38: 217–219. Medline Weidle PJ. 1996. Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus. Am J Health-Syst Pharm 53: 368–378. Weinroth SE, Parenti DM, Simon GL. 1995. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 4: 76–94. Medline WHO Expert Committee on Leprosy Sixth Report. 1988. WHO Technical Report Series No. 768. Winberg AJ. 1964. Utredning rörande det eventuella sambandet mellan fosterskador och läkemedel. Särtryck Svenska Läkartidningen. 61: 1–63. Yang Q, Khoury MJ, James LM, Olney RS, Paulozzi LJ, Erickson JD. 1997. The return of thalidomide: are birth defects surveillance systems ready? Am J Med Genet 73: 251–258. Medline Yazici H, Yurdakul S, Hamuryudan V. 1999. Behcet's syndrome. Curr Opin Rheumatol 11; 53–57. Medline Zetterström B. 1966. Ocular malformation caused by thalidomide. Acta Ophthalmol 44: 391–395. Zhu J, Deng GM, Diab A, Zwingenberger K, Bakhiet M, Link H. 1998. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats. Scand J Immunol 48: 397–402. Medline Zwingenberger K, Wendt S. 1996. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm 46: 177–211. Citing Literature Volume60, Issue5November 1999Pages 306-321 ReferencesRelatedInformation
Referência(s)